MejorAspTM PEG L – Asparaginase Injection 3750 IU/5ml


Sayre Therapeutics offers clinicians a PEG L – Asparaginase formulation proven to be effective in Acute Lymphoblastic Leukemia (ALL)

  • Indication: MejorAsp ™ is indicated as a component of a multi agent chemotherapeutic regimen for the treatment of patients with Acute Lymphoblastic Leukemia who are hypersensitive to asparaginase.
  • Formulation: PEG L –Asparaginase Injection for intravenous or intramuscular administration
  • MejorAsp ™
    • Offers lower dosing across longer intervals i. e. 2500IU/sq. mt. every 14 days.
    • Offers slower clearance from plasma with lesser half life (6 days), hence lesser allergic reactions.
    • Reduces risk of high titer Antibodies (Abs) formation, hence no loss of enzyme activity.

MejorAsp ™ is manufactured by a US FDA approved biotechnology plant – Certified by WHO-GMP and ISO 9000:2001, Therapeutic Goods Administration, Australia (TGA) and by the European Union’s Certificate Of Suitability (COS).

For more information regarding MejorAsp TM, please contact your local Sales Representative or email us at